Splisense
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.
Splisense is a business in biotechnology, life science, pharmaceutical based in Europe, Middle East, and Africa (EMEA), Middle East, Middle East and North Africa (MENA), founded in 2016.
Its activity falls under biotechnology, life science, pharmaceutical; the profile below is assembled from public directory data.
Its base of operations is Europe, Middle East, and Africa (EMEA), Middle East, Middle East and North Africa (MENA).
Directory data places it at the Series_B stage.
Its team size is recorded as c_00011_00050 employees.
It has disclosed roughly $28.5M in funding.
| Sector | Biotechnology, Life Science, Pharmaceutical |
|---|---|
| Headquarters | Europe, Middle East, and Africa (EMEA), Middle East, Middle East and North Africa (MENA) |
| Founded | 2016 |
| Employees | c_00011_00050 |
| Stage | series_b |
| Total funding | $28,500,000 |
Website: splisense.com
Sign in to view the contact information we hold for Splisense.
Create a free account
Create a free account